PTC Therapeutics 미래 성장

Future 기준 확인 0/6

PTC Therapeutics은 연간 수입과 매출이 각각 55.8%와 7.8% 증가할 것으로 예상되고 EPS는 연간 54.4%만큼 증가할 것으로 예상됩니다.

주요 정보

55.8%

수익 성장률

54.4%

EPS 성장률

Biotechs 수익 성장	27.2%
매출 성장률	7.8%
향후 자기자본 수익률	n/a
애널리스트 커버리지	Good
마지막 업데이트	29 Jan 2025

최근 미래 성장 업데이트

Recent updates

PTC Therapeutics, Inc.'s (NASDAQ:PTCT) Price Is Right But Growth Is Lacking After Shares Rocket 29%

Dec 03

PTC Therapeutics: ALS Drug Fail Kicks Off Critical Year Of Catalysts

Nov 29

PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Fly 29% But Investors Aren't Buying For Growth

Oct 09

PTC Therapeutics: Positive HD Data Along With NDA Submission Brings Further Value

Sep 12

Little Excitement Around PTC Therapeutics, Inc.'s (NASDAQ:PTCT) Revenues

Jun 28

PTC Therapeutics: Riding The Regulatory Rollercoaster With Translarna

May 22

Industry Analysts Just Upgraded Their PTC Therapeutics, Inc. (NASDAQ:PTCT) Revenue Forecasts By 11%

May 22

PTC Therapeutics: Multiple Regulatory Submissions Along With Data Cuts

May 14

PTC Therapeutics, Inc. (NASDAQ:PTCT) Surges 27% Yet Its Low P/S Is No Reason For Excitement

Mar 03

PTC Therapeutics: Already Generates Revenues, But Lots Of Outstanding Options

Feb 11

An Intrinsic Calculation For PTC Therapeutics, Inc. (NASDAQ:PTCT) Suggests It's 49% Undervalued

Jun 23

Benign Growth For PTC Therapeutics, Inc. (NASDAQ:PTCT) Underpins Its Share Price

May 18

An Intrinsic Calculation For PTC Therapeutics, Inc. (NASDAQ:PTCT) Suggests It's 49% Undervalued

Mar 02

PTC pauses enrollment in mid-stage study for Huntington's disease candidate in U.S.

Oct 19

수익 및 매출 성장 예측

NasdaqGS:PTCT - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2027	996	-81	259	N/A	6
12/31/2026	858	-147	151	207	12
12/31/2025	971	-51	51	2	14
12/31/2024	814	-341	133	-42	6
9/30/2024	901	-453	-274	-178	N/A
6/30/2024	900	-480	-230	-115	N/A
3/31/2024	928	-579	-199	-58	N/A
12/31/2023	938	-627	-279	-158	N/A
9/30/2023	798	-642	-343	-224	N/A
6/30/2023	819	-618	-364	-248	N/A
3/31/2023	770	-571	-403	-289	N/A
12/31/2022	699	-559	-509	-357	N/A
9/30/2022	697	-531	-409	-260	N/A
6/30/2022	618	-556	-422	-273	N/A
3/31/2022	569	-522	-395	-249	N/A
12/31/2021	539	-524	-337	-251	N/A
9/30/2021	492	-455	-327	-247	N/A
6/30/2021	472	-391	-250	-169	N/A
3/31/2021	430	-454	-271	-213	N/A
12/31/2020	381	-438	-250	-194	N/A
9/30/2020	358	-441	-193	-140	N/A
6/30/2020	311	-432	-221	-182	N/A
3/31/2020	322	-292	-198	-138	N/A
12/31/2019	307	-252	-144	-99	N/A
9/30/2019	297	-222	-142	-104	N/A
6/30/2019	279	-213	-116	-85	N/A
3/31/2019	262	-181	-72	-54	N/A
12/31/2018	265	-128	-43	-28	N/A
9/30/2018	256	-78	0	9	N/A
6/30/2018	245	-61	N/A	-10	N/A
3/31/2018	224	-69	N/A	3	N/A
12/31/2017	194	-79	N/A	-10	N/A
9/30/2017	142	-107	N/A	-45	N/A
6/30/2017	123	-108	N/A	-53	N/A
3/31/2017	90	-130	N/A	-91	N/A
12/31/2016	83	-142	N/A	-104	N/A
9/30/2016	70	-166	N/A	-121	N/A
6/30/2016	57	-174	N/A	-124	N/A
3/31/2016	48	-174	N/A	-129	N/A
12/31/2015	37	-170	N/A	-124	N/A
9/30/2015	37	-147	N/A	-102	N/A
6/30/2015	29	-131	N/A	-91	N/A
3/31/2015	24	-118	N/A	-80	N/A
12/31/2014	25	-94	N/A	-57	N/A
9/30/2014	17	-84	N/A	-64	N/A
6/30/2014	32	-62	N/A	-52	N/A
3/31/2014	37	-51	N/A	-53	N/A

애널리스트 미래 성장 예측

수입 대 저축률: PTCT 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: PTCT 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: PTCT 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: PTCT 의 수익(연간 7.8% ) US 시장( 8.9% 보다 느리게 성장할 것으로 예상됩니다. 8.9% 연간).

고성장 수익: PTCT 의 수익(연간 7.8% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: PTCT 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

성장 기업 발견

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2025/01/30 04:04
장 마감 주가	2025/01/30 00:00
수익	2024/09/30
연간 수익	2023/12/31

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.

애널리스트 출처

PTC Therapeutics, Inc. 27 애널리스트 중 14 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Joel Beatty	Baird
Huidong Wang	Barclays
Geoffrey Meacham	Barclays

PTC Therapeutics 미래 성장

Future 기준 확인 0/6

주요 정보

최근 미래 성장 업데이트

Forecast to breakeven in 2025

PTC Therapeutics, Inc. Provides Revenue Guidance for the Year 2025

Price target increased by 7.6% to US$48.43

Price target increased by 8.4% to US$45.00

PTC Therapeutics, Inc. Provides Revenue Guidance for the Full Year 2024

Consensus revenue estimates increase by 11%

Recent updates

Forecast to breakeven in 2025

PTC Therapeutics, Inc. Provides Revenue Guidance for the Year 2025

CEO & Director recently sold US$374k worth of stock

CEO & Director notifies of intention to sell stock

PTC Therapeutics, Inc. Announces Vatiquinone NDA Submission to FDA for the Treatment of Children and Adults Living with Friedreich Ataxia

Executive VP & Chief Legal Officer notifies of intention to sell stock

PTC Therapeutics, Inc.'s (NASDAQ:PTCT) Price Is Right But Growth Is Lacking After Shares Rocket 29%

Price target increased by 7.6% to US$48.43

PTC Therapeutics: ALS Drug Fail Kicks Off Critical Year Of Catalysts

An undisclosed buyer entered into an agreement to acquire Rare Pediatric Disease Priority Review Voucher of PTC Therapeutics, Inc. from PTC Therapeutics, Inc. (NasdaqGS:PTCT) for $150 million.

PTC Therapeutics, Inc. Announces Topline Results of Cardinals Trial of Utreloxastat in ALS Patients

Price target increased by 8.4% to US$45.00

PTC Therapeutics, Inc. Announces FDA Approval of AADC Deficiency Gene Therapy

New minor risk - Profitability

New minor risk - Shareholder dilution

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

PTC Therapeutics, Inc. Provides Revenue Guidance for the Full Year 2024

PTC Therapeutics Announces FDA Acceptance of Translarna NDA Resubmission

PTC Therapeutics, Inc. Announces Committee for Medicinal Products for Human Use of the European Medicines Agency Maintains Negative Opinion on Translarna Reexamination

PTC Therapeutics Announces FDA Target Regulatory Action Date for Sepiapterin and Lancet Publication of Phase 3 Trial Results

PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Fly 29% But Investors Aren't Buying For Growth

PTC Therapeutics, Inc. Announces Positive Results from Long-Term Treatment Studies and Updates on Regulatory Progress for Vatiquinone Friedreich Ataxia Program

PTC Therapeutics Announces FDA Acceptance for Filing of NDA for Sepiapterin for the Treatment of Pediatric and Adult Phenylketonuria Patients

PTC Therapeutics: Positive HD Data Along With NDA Submission Brings Further Value

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

PTC Therapeutics, Inc. Announces Sepiapterin Nda Submission to Fda

Little Excitement Around PTC Therapeutics, Inc.'s (NASDAQ:PTCT) Revenues

PTC Therapeutics, Inc. Announces Interim PIVOT-HD Results from the Phase 2 PIVOT-HD Study of PTC518 in Huntington's Disease Patients

PTC Therapeutics: Riding The Regulatory Rollercoaster With Translarna

Industry Analysts Just Upgraded Their PTC Therapeutics, Inc. (NASDAQ:PTCT) Revenue Forecasts By 11%

Consensus revenue estimates increase by 11%

New minor risk - Share price stability

PTC Therapeutics Announces FDA Acceptance and Priority Review of the BLA for Upstaza

PTC Therapeutics: Multiple Regulatory Submissions Along With Data Cuts

Consensus revenue estimates increase by 11%

PTC Therapeutics, Inc., Annual General Meeting, Jun 18, 2024

PTC Therapeutics, Inc. Provides Earnings Guidance for the Year 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

PTC Therapeutics, Inc. to Report Q1, 2024 Results on Apr 25, 2024

PTC Therapeutics, Inc. Announces Submission of Sepiapterin MAA for Treatment of PKU to EMA

ClearPoint Neuro Congratulates its Partner PTC Therapeutics on Completion of Biologics License Application Submission to FDA for Upstaza™ as a Treatment for AADC Deficiency

PTC Therapeutics, Inc. (NASDAQ:PTCT) Surges 27% Yet Its Low P/S Is No Reason For Excitement

Full year 2023 earnings: EPS misses analyst expectations

PTC Therapeutics, Inc. Provides Earnings Guidance for the Year 2024

PTC Therapeutics, Inc. to Report Q4, 2023 Results on Feb 29, 2024

PTC Therapeutics: Already Generates Revenues, But Lots Of Outstanding Options

CHMP Issues Negative Opinion for Renewal of Conditional Marketing Authorization for Translarn (ataluren) Following Re-examination Procedure

Co-Founder notifies of intention to sell stock

CEO & Director recently sold US$274k worth of stock

PTC Therapeutics, Inc. Provides Revenue Guidance for the Full-Year of 2024

CEO & Director notifies of intention to sell stock

PTC Therapeutics, Inc. Provides Updates on Translarna Regulatory Activities

Consensus EPS estimates fall by 10%

PTC Therapeutics, Inc. Updates Revenue Guidance for Full Year 2023

Third quarter 2023 earnings: EPS misses analyst expectations

PTC Therapeutics, Inc. to Report Q3, 2023 Results on Oct 26, 2023

New major risk - Financial position

Price target decreased by 12% to US$45.64

New major risk - Financial position

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

PTC Therapeutics, Inc. Provides Revenue Guidance for the Full Year 2023

PTC Therapeutics, Inc. to Report Q2, 2023 Results on Aug 03, 2023

PTC Therapeutics, Inc. Announces Results from MIT-E Clinical Trial of Vatiquinone for the Treatment of Mitochondrial Disease Associated Seizures

An Intrinsic Calculation For PTC Therapeutics, Inc. (NASDAQ:PTCT) Suggests It's 49% Undervalued

Ptc Therapeutics Shares Positive Interim Data from Pivot-Hd Clinical Trial in Huntington's Disease Patients

PTC Therapeutics, Inc. Announces Strategic Pipeline Prioritization

Consensus EPS estimates upgraded to US$4.26 loss

PTC Therapeutics, Inc. Announces Cessation of Emily Hill as Chief Financial Officer, Effective on August 20, 2023

Price target increased by 8.6% to US$57.64